Osteoporosis International

, Volume 22, Issue 9, pp 2551–2556 | Cite as

Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study

  • P. N. Sambrook
  • I. D. Cameron
  • J. S. Chen
  • L. M. March
  • J. M. Simpson
  • R. G. Cumming
  • M. J. Seibel
Short Communication

Abstract

Summary

In a study of 2005 institutionalized older people, use of oral bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for potential confounders.

Introduction

This study investigated whether reductions in mortality reported in a trial of intravenous zoledronate after hip fracture could be seen in older people taking oral bisphosphonates.

Methods

Two thousand and five institutionalized older people (mean age 85.7 years) were assessed at baseline and followed up for hip fracture and death for at least 5 years. Cox proportional hazards regression was used to estimate effects of bisphosphonates on risk of death.

Results

At baseline, 78 subjects were taking oral bisphosphonates. Over 5 years of follow-up, 1,596 participants (80%) died. Use of bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for age, gender, type of institution, immobility, number of medications, weight, cognitive function, co-morbidities, and hip fracture incidence during the follow-up period (hazard ratio 0.73; 95% CI, 0.56 to 0.94; P = 0.02).

Conclusion

Oral bisphosphonates are associated with a reduction in the risk of death in the elderly. The mechanism of effect requires further investigation.

Keywords

Aged care facility Elderly Hip fracture Mortality Osteoporosis 

Notes

Acknowledgements

This study was supported by grants from the Australian National Health and Medical Research Council, Osteoporosis Australia, and Arthritis Australia.

Conflicts of interest

None.

References

  1. 1.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRefGoogle Scholar
  2. 2.
    Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE (1989) Survival experience of aged hip fracture patients. Am J Public Health 79:274–278PubMedCrossRefGoogle Scholar
  3. 3.
    Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  4. 4.
    Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRefGoogle Scholar
  5. 5.
    Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRefGoogle Scholar
  6. 6.
    Sambrook PN, Chen CJ, March L, Cameron ID, Cumming RG, Lord SR, Simpson JM, Seibel MJ (2006) High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21:549–555PubMedCrossRefGoogle Scholar
  7. 7.
    Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ, Sambrook PN (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res 25:866–872PubMedGoogle Scholar
  8. 8.
    Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, Zochling J, Sitoh YY, Lau TC, Schwarz J, Seibel MJ (2004) Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 89:1572–1576PubMedCrossRefGoogle Scholar
  9. 9.
    Zochling J, Sitoh YY, Lau TC, Cameron ID, Cumming RG, Lord SR, Schwarz J, Trube A, March LM, Sambrook PN (2002) Quantitative ultrasound of the calcaneus and falls risk in the institutionalized elderly: sex differences and relationship to vitamin D status. Osteoporos Int 13:882–887PubMedCrossRefGoogle Scholar
  10. 10.
    Holtzman J, Lurie N (1996) Causes of increasing mortality in a nursing home population. J Am Geriatr Soc 44:258–264PubMedGoogle Scholar
  11. 11.
    Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  12. 12.
    Bliuc D, Nguyen N, Nguyen T, Eisman JA, Center J (2009) Relationship Between Low BMD And Fracture In Mortality Risk: An 18-Year Prospective Study From Dubbo Osteoporosis Epidemiology Study. 31st Annual Meeting of American Society for Bone and Mineral Research Abst FR0329Google Scholar
  13. 13.
    Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31–38PubMedCrossRefGoogle Scholar
  14. 14.
    Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite AE (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371–380PubMedCrossRefGoogle Scholar
  15. 15.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  16. 16.
    Szulc P, Maurice C, Marchand F, Delmas PD (2009) Increased bone resorption is associated with higher mortality in community-dwelling men > or = 50 years of age: the MINOS study. J Bone Miner Res 24:1116–1124PubMedCrossRefGoogle Scholar
  17. 17.
    Szulc P, Samelson EJ, Kiel DP, Delmas PD (2009) Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study. J Bone Miner Res 24:2023–2031PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • P. N. Sambrook
    • 1
  • I. D. Cameron
    • 2
  • J. S. Chen
    • 1
  • L. M. March
    • 1
  • J. M. Simpson
    • 3
  • R. G. Cumming
    • 4
  • M. J. Seibel
    • 5
  1. 1.Institute of Bone and Joint ResearchUniversity of SydneySt LeonardsAustralia
  2. 2.Rehabilitation Studies UnitUniversity of SydneySydneyAustralia
  3. 3.Sydney School of Public HealthUniversity of SydneySydneyAustralia
  4. 4.Centre for Education and Research on AgeingUniversity of SydneySydneyAustralia
  5. 5.ANZAC Research InstituteUniversity of SydneySydneyAustralia

Personalised recommendations